PTC THERAPEUTICS, INC. (PTCT)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues-Manufacturing | - | - | - | - |
| Royalty | 57,605 | - | - | - |
| Product | 118,329 | - | - | - |
| Collaboration And License Revenue | 2,941 | - | - | - |
| Total revenues | 178,875 | - | - | - |
| Change in the fair value of contingent consideration | - | 800 | -700 | -5,100 |
| Selling, general and administrative | 85,262 | 80,961 | 73,456 | 69,500 |
| Research and development | 112,990 | 108,973 | 161,412 | 132,169 |
| Amortization of acquired intangible assets | 4,061 | 3,798 | 3,036 | 2,865 |
| Tangible asset impairment and losses (gains) on transactions, net | -99 | -77 | -1,844 | -1,761 |
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | 11,420 | 12,862 | 10,848 | 15,527 |
| Total operating expenses | 213,832 | 205,871 | 251,296 | 226,922 |
| Revenue | - | 1,176,096 | 196,786 | 186,704 |
| (loss) income from operations | -34,957 | 970,225 | -54,510 | -40,218 |
| Interest expense, net | -30,358 | -34,092 | -41,609 | -43,490 |
| Other expense, net | -5,737 | -6,305 | -1,872 | -2,025 |
| (loss) income before income tax benefit (expense) | -71,052 | 929,828 | -97,991 | -85,733 |
| Income tax benefit (expense) | -6,203 | 63,266 | 8,663 | 13,446 |
| Net (loss) income attributable to common stockholders | -64,849 | 866,562 | -106,654 | -99,179 |
| Earnings per share, basic | -0.83 | 11.09 | -1.39 | -1.29 |
| Earnings per share, diluted | -0.83 | 10.04 | -1.39 | -1.29 |
| Weighted average number of shares outstanding, basic | 78,151,240 | 78,115,836 | 76,925,523 | 76,725,070 |
| Weighted average number of shares outstanding, diluted | 78,151,240 | 86,385,922 | 76,925,523 | 76,725,070 |